Collegium Pharmaceutical (NasdaqGS:COLL) - Share price, News & Analysis

COLL fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	4/6
Past Performance	2/6
Financial Health	0/6
Dividends	0/6

COLL Stock Overview

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management.

Rewards

Trading at 91% below our estimate of its fair value

Earnings are forecast to grow 33.13% per year

Earnings have grown 72.5% per year over the past 5 years

Risk Analysis

Interest payments are not well covered by earnings

Large one-off items impacting financial results

Collegium Pharmaceutical Competitors

Viatris

NasdaqGS:VTRS

US$14.1b

Teva Pharmaceutical Industries

NYSE:TEVA

US$9.4b

Pacira BioSciences

NasdaqGS:PCRX

US$2.9b

Supernus Pharmaceuticals

NasdaqGM:SUPN

US$1.5b

Price History & Performance

Summary of all time highs, changes and price drops for Collegium Pharmaceutical
Historical stock prices
Current Share Price	US$15.65
52 Week High	US$25.66
52 Week Low	US$14.04
Beta	1.06
1 Month Change	-11.33%
3 Month Change	-29.41%
1 Year Change	-36.18%
3 Year Change	32.18%
5 Year Change	77.84%
Change since IPO	27.34%

Shareholder Returns

	COLL	US Pharmaceuticals	US Market
7D	0.9%	0.5%	-0.5%
1Y	-36.2%	11.8%	-12.3%

Return vs Industry: COLL underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.

Return vs Market: COLL underperformed the US Market which returned -12.9% over the past year.

Price Volatility

Is COLL's price volatile compared to industry and market?
COLL volatility
COLL Average Weekly Movement	6.3%
Pharmaceuticals Industry Average Movement	11.9%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	2.9%

Stable Share Price: COLL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: COLL's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2002	152	Joe Ciaffoni	https://www.collegiumpharma.com

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.

Collegium Pharmaceutical Fundamentals Summary

How do Collegium Pharmaceutical's earnings and revenue compare to its market cap?
COLL fundamental statistics
Market Cap	US$531.68m
Earnings (TTM)	US$42.79m
Revenue (TTM)	US$272.90m

12.4x

P/E Ratio

1.9x

P/S Ratio

Is COLL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
COLL income statement (TTM)
Revenue	US$272.90m
Cost of Revenue	US$60.07m
Gross Profit	US$212.82m
Other Expenses	US$170.04m
Earnings	US$42.79m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	1.26
Gross Margin	77.99%
Net Profit Margin	15.68%
Debt/Equity Ratio	392.0%

How did COLL perform over the long term?

See historical performance and comparison

Valuation

Is Collegium Pharmaceutical undervalued compared to its fair value and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: COLL ($15.65) is trading below our estimate of fair value ($174.4)

Significantly Below Fair Value: COLL is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: COLL is good value based on its PE Ratio (12.4x) compared to the US Pharmaceuticals industry average (20.1x).

PE vs Market: COLL is good value based on its PE Ratio (12.4x) compared to the US market (15.1x).

Price to Earnings Growth Ratio

PEG Ratio: COLL is good value based on its PEG Ratio (0.4x)

Price to Book Ratio

PB vs Industry: COLL is overvalued based on its PB Ratio (2.7x) compared to the US Pharmaceuticals industry average (1.8x).

Future Growth

How is Collegium Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

33.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: COLL's forecast earnings growth (33.1% per year) is above the savings rate (1.9%).

Earnings vs Market: COLL's earnings (33.1% per year) are forecast to grow faster than the US market (12.5% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: COLL's revenue (8.4% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: COLL's revenue (8.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if COLL's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Collegium Pharmaceutical performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

72.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: COLL has a large one-off loss of $34.0M impacting its March 31 2022 financial results.

Growing Profit Margin: COLL's current net profit margins (15.7%) are higher than last year (13.1%).

Past Earnings Growth Analysis

Earnings Trend: COLL has become profitable over the past 5 years, growing earnings by 72.5% per year.

Accelerating Growth: COLL's earnings growth over the past year (2%) is below its 5-year average (72.5% per year).

Earnings vs Industry: COLL earnings growth over the past year (2%) underperformed the Pharmaceuticals industry 16.9%.

Return on Equity

High ROE: Whilst COLL's Return on Equity (21.82%) is high, this metric is skewed due to their high level of debt.

Financial Health

How is Collegium Pharmaceutical's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: COLL's short term assets ($363.6M) do not cover its short term liabilities ($373.6M).

Long Term Liabilities: COLL's short term assets ($363.6M) do not cover its long term liabilities ($676.5M).

Debt to Equity History and Analysis

Debt Level: COLL's net debt to equity ratio (337.6%) is considered high.

Reducing Debt: COLL's debt to equity ratio has increased from 3% to 392% over the past 5 years.

Debt Coverage: COLL's debt is not well covered by operating cash flow (7.5%).

Interest Coverage: COLL's interest payments on its debt are not well covered by EBIT (1x coverage).

Balance Sheet

Dividend

What is Collegium Pharmaceutical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate COLL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate COLL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if COLL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if COLL's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as COLL has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure

CEO

Joe Ciaffoni (50 yo)

3.83yrs

Tenure

US$7,314,335

Compensation

Mr. Joseph J. Ciaffoni, also known as Joe, has been Chief Executive Officer and Director of Collegium Pharmaceutical, Inc. since July 1, 2018 and also has been its President since July 2018. Mr. Ciaffoni s...

CEO Compensation Analysis

Compensation vs Market: Joe's total compensation ($USD7.31M) is above average for companies of similar size in the US market ($USD2.60M).

Compensation vs Earnings: Joe's compensation has increased by more than 20% in the past year.

Leadership Team

Experienced Management: COLL's management team is considered experienced (3.1 years average tenure).

Board Members

Experienced Board: COLL's board of directors are considered experienced (7.8 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/24 00:00
End of Day Share Price	2022/05/23 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31